RCH-01
An autologous cell therapy whose Japanese licence RepliCel terminated in 2021, and which has produced little public news since.
Phase 2Cell therapyStem cell activation
This programme is no longer being actively pursued.
- Developed by
- RepliCel Life Sciences
- Current phase
- Phase 2
- Partners
- Shiseido
- Indications
- Androgenetic alopecia
- Also known as
- RCH01, Replicel RCH-01
- Last public activity
- Never
- Record confidence
- Medium
Tests whether it works, at what dose, in a few hundred people.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
No trials matched to this programme in ClinicalTrials.gov.
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- RepliCel Terminates License Agreement with Shiseido — Company release, December 2021